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Summary
Background Infant rotavirus vaccines have led to substantial reductions in hospital admissions and deaths due to 
gastroenteritis, but some studies have reported an elevated risk of intussusception, a rare bowel disorder. This analysis 
aimed to provide evidence on the potential mortality reduction benefits and intussusception risks of current rotavirus 
vaccination schedules, and to explore whether alternative schedules could have advantages.
Methods All 135 low-income and middle-income countries, defined by gross national income per capita of less than 
US$12 236 in the 2018 fiscal year, were included in the model. Mortality reduction benefits and intussusception risks 
of rotavirus vaccination were modelled by use of an Excel-based static cohort model with a finely disaggregated age 
structure. Numbers of rotavirus gastroenteritis deaths and intussusception deaths in each week of age were 
calculated for all infants born in the year 2015 between birth and age 5·0 years, with and without restrictions on age 
at administration. Benefit–risk ratios (rotavirus gastroenteritis deaths prevented per excess intussusception death) 
and other indicators were calculated for two vaccination schedules currently recommended by WHO and 
16 alternative schedules. Of these schedules, it was assumed that between one and three doses would be given; the 
first dose of the rotavirus vaccine would be co-administered with either BCG or diphtheria–tetanus–pertussis 
(DTP)1; and the second or third dose would be co-administered with either DTP1, DTP2, DTP3, or measles (Meas)1.
Findings A three-dose schedule co-administered with DTP (without age restrictions) could prevent about 74 000 
(95% uncertainty interval 59 000–100 000) rotavirus gastroenteritis deaths (38% reduction) and could lead to 
201 (77–550) excess intussusception deaths (1·4% increase) compared with no vaccination, resulting in a benefit–risk 
ratio of 369:1 (160:1–895:1). The benefit–risk ratio was most favourable when the relative risk of intussusception was 
assumed to decline with the national under-5 mortality rate (2386:1) and least favourable with pessimistic assumptions 
about access to hospital for intussusception treatment (168:1). Schedules that involve giving the first dose with BCG 
and the second with DTP1 had the fewest excess intussusception deaths and most favourable benefit–risk ratios.
Interpretation Rotavirus vaccines have a favourable benefit–risk profile in LMICs. Neonatal schedules have the 
potential to prevent more rotavirus gastroenteritis deaths and cause fewer excess intussusception deaths than the 
schedules currently recommended by WHO, but more efficacious rotavirus vaccines would be needed to achieve 
more substantial mortality reduction benefits.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Infant rotavirus vaccines have led to substantial reductions 
in hospital admissions for gastroenteritis,1 but some 
studies have reported an elevated risk of intussusception, a 
rare bowel disorder.2,3 In 2012, modelled estimates of the 
potential benefits and risks of introducing rotavirus 
vaccines into the national immunisation programmes of 
158 countries provided reassurance about the highly 
positive benefit–risk profile of these vaccines.4 This 
analysis also informed a WHO recommendation to 
remove the manufacturers’ age restrictions for vaccine 
administration in settings where the mortality reduction 
benefits of late vaccination greatly exceeded the 
intussusception risk.5 Since the 2012 analysis, estimates of 
the number of rotavirus gastroenteritis deaths in children 
younger than 5 years (without vaccination) have decreased 
from about 450 000 in 2008 to about 200 000 in 2015.6 The 
evidence for several other modelling parameters has also 
been substantially strengthened, including new estimates 
of the efficacy of live oral rotavirus vaccines by duration of 
follow-up;7 the age distribution of rotavirus gastroenteritis 
hospital admissions in children younger than 5 years;8 
intussusception incidence rates, age distributions, and 
case fatality ratios in children younger than 5 years;9 and 
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the relative risk (RR) of intussusception 1–7 days and 
8–21 days after administration of the first two doses of 
rotavirus vaccination,10 including the first risk estimates 
from high-mortality settings.11,12 Hence, it is now pos sible to 
produce updated and more robust benefit–risk estimates.
The scale of benefits and risks due to rotavirus 
vaccination will depend on the choice of vaccination 
schedule. For programmatic and economic reasons, 
rotavirus vaccines are currently co-administered with 
diphtheria–tetanus–pertussis (DTP)-containing vaccines 
in the first 6 months of life. More than half the countries 
in the world have introduced rotavirus vaccines. 
Countries either give two doses with DTP1 and DTP2, or 
three doses with DTP1, DTP2, and DTP3 as per current 
WHO recommendations. Randomised controlled trials 
using these schedules have shown high and durable 
rotavirus vaccine efficacy in high-income countries but 
lower and less durable efficacy in low-income and 
middle-income countries (LMICs).7 These trials have 
stimulated interest in the potential value of a neonatal 
dose given at the same time as BCG, a booster dose 
given with the first dose of measles vaccine (Meas1), or 
both. A neonatal dose has the potential to prevent 
disease that occurs very early in life and has been shown 
to be highly efficacious in Indonesia when administered 
as part of a three-dose schedule.13 A booster dose has the 
potential to mitigate the effects of waning rotavirus 
vaccine protection and has been shown to be non-
interfering and immune-boosting in trials.14,15 The 
optimal number and timing of doses (concurrent with 
different combinations of BCG, DTP1, DTP2, DTP3, and 
Meas1) will depend on several factors, including the 
balance of benefits to risks.
The aim of this study was to investigate the potential 
mortality reduction benefits and intussusception risks of 
current rotavirus vaccination schedules in LMICs and 
to explore whether alternative schedules could have 
advantages. 
Methods
Model design
All countries with a gross national income per capita of 
less than US$12 236 in the 2018 fiscal year were included 
in the model.16 An Excel-based static cohort model with a 
finely disaggregated age structure (weeks of age up to 
5 years) was used to calculate potential benefits and risks 
of vaccination.17 In each country, the model was used to 
calculate numbers of doses administered, fully vaccinated 
infants, rotavirus gastroenteritis deaths, intussusception 
cases, and intussusception deaths expected to occur 
among all infants born in the year 2015 from birth to age 
5.0 years. Estimated benefits (rotavirus gastroenteritis 
deaths averted) and risks (excess intussusception cases 
and deaths) were calculated by comparing each schedule 
scenario to a scenario with no rotavirus vaccination. The 
incremental benefits and risks of moving from age-
restricted schedules to age-unrestricted schedules were 
also calculated. The primary outcome measure was the 
benefit–risk ratio of rotavirus vaccination (number of 
rotavirus gastroenteritis deaths prevented per excess 
Research in context
Evidence before this study
We searched PubMed (“rotavirus vaccines” AND “risk 
assessment”) without language restrictions, from database 
inception until Sept 5, 2019, and identified 11 studies on 
benefit–risk assessments published between May, 2009, 
and September, 2018. In eight studies of low-mortality 
countries (Australia, England, two in France, Japan, the 
Netherlands, Singapore, and the USA), deaths from rotavirus or 
intussusception were very rare. Three studies evaluated multiple 
higher mortality countries. In the most recent study, published 
in 2012, the number of gastroenteritis deaths prevented per 
excess intussusception death was 371:1 for an age-restricted 
schedule co-administered with diphtheria–tetanus–pertussis, 
indicating a highly positive benefit–risk profile for rotavirus 
vaccination. This study also informed a WHO recommendation 
to remove the manufacturers’ age restrictions for vaccination 
given that the benefits of preventing additional rotavirus 
mortality from later vaccination greatly exceeded the 
intussusception risks (a benefit–risk ratio of 154:1).
Added value of this study
This analysis, based on updated evidence, provides continued 
reassurance about the highly positive benefit–risk profile of 
infant rotavirus vaccines. It provides modelled estimates of the 
number of rotavirus gastroenteritis and intussusception deaths 
for a range of different rotavirus vaccination schedules and 
scenarios. These results can be scrutinised at the national level 
and used to inform decision making in low-income and middle-
income countries. 
Implications of all the available evidence
This analysis supports the WHO recommendations to include 
rotavirus vaccination in national immunisation programmes 
and to remove age restrictions in countries where the mortality 
reduction benefits of late vaccination greatly exceed the risks. 
Schedules that involve giving the first dose with BCG and the 
second dose with diphtheria–tetanus–pertussis 1 could further 
increase effect and reduce risks, but more studies are required 
to assess their safety. There is a need for improved estimates of 
the proportion of children with timely access to intussusception 
treatment.
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intussusception death). Other indicators were the 
percent reduction in rotavirus gastroenteritis deaths, 
percent increase in intussusception deaths, number of 
fully vaccinated infants per excess intussusception case, 
and number of rotavirus gastroenteritis deaths prevented 
per dose administered.
Vaccination schedule scenarios
Several licensed rotavirus vaccines are available 
nowadays, but evidence from comparisons in the same 
populations is insufficient to show conclusive superiority 
of one brand over another in terms of vaccine efficacy, 
effectiveness, or impact,3,18–20 or intussusception risks.3,21 
Thus, all currently licensed vaccines were assumed to be 
equivalent in these respects. To restrict the vaccine 
schedules considered to a manageable number, it was 
assumed that between one and three doses would be 
given; the first dose of the rotavirus vaccine would be co-
administered with either BCG or DTP1; and the second 
or third dose would be co-administered with either 
DTP1, DTP2, DTP3, or Meas1. This approach resulted in 
18 possible schedules (table 1). For the first 11 schedule 
options (all primary dose schedules), scenarios with 
and without strict adherence to age restrictions were 
modelled (first dose administered before 15 weeks of 
age; last dose delivered before 32 weeks of age). 
Potential benefits of rotavirus vaccination
For a given country and week (w) of age, the number of 
rotavirus gastroenteritis deaths was calculated as: 
where PY × M × Aw is the number of rotavirus gastro-
enteritis deaths in week w of age; Vw is the direct effect of 
vaccination in week w of age; PY is the number of person-
years lived between birth and age 5·0 years in the 2015 
birth cohort;22 M is the rotavirus gastroenteritis mortality 
rate per 100 000 population per year among children 
younger than 5 years before the introduction of rotavirus 
vaccination; Aw is the proportion of rotavirus deaths in 
children younger than 5 years in week w of age.
The direct effect of vaccination in each week of age (Vw) 
was calculated as:
where C3w × E3w is the direct effect contributed by infants 
that received all three doses; (C2w – C3w) × E2w the direct 
effect contributed by infants that received only two doses; 
(C1w – C2w) × E1w the direct effect contributed by infants that 
received only one dose; C1w, C2w, and C3w are coverage 
estimates for the first three doses of rotavirus vaccination 
in week w of age, each adjusted for age restrictions if 
applicable; and E1w, E2w, and E3w are efficacy estimates for 
the first three doses of rotavirus vaccination in week w of 
age, each adjusted for waning since the time of 
vaccination. All parameters used to estimate benefits are 
defined in the appendix (pp 1, 2, 16).
Potential risks of rotavirus vaccination
For a given country, dose d, and week w of age, the 
number of excess (vaccine-related) intussusception 
events (eg, cases or deaths) was calculated as:
where P × (Cd, w – Cd, w – 1) is the number of infants receiving 
dose d in week w of age, Bw × (RRd, 1 – 7 – 1) is the rate of 
intussusception 1–7 days after dose d in week w of age, 
Bw + 1 × (RRd, 8 – 14 – 1) is the rate of intussusception 8–14 days 
after dose d in week w of age, Bw + 2 × (RRd, 15 – 21 – 1) is the rate 
of intussusception 15–21 days after dose d in week w of 
age, and P is the mid-year population for the relevant 
single year of age; Cd, w and Cd, w – 1 are cumulative coverage 
estimates for dose d in weeks w and w–1, respectively; Bw, 
Bw + 1, and Bw + 2 are the background rates of intussusception 
events in weeks w, w + 1, and w + 2 of age, respectively; and 
RRd, 1 – 7, RRd, 8 – 14, RRd, 15 – 21 are the relative risks of vaccine-
related intus susception associated with dose d in the 
periods 1–7 days, 8–14 days, and 15–21 days after 
vaccination, respectively. RRs were assumed to be only 
dose-dependent, with no independent effect of age of 
vaccine administration. All parameters used to estimate 
risks are defined in the appendix (pp 3, 4, 16).
Neonatal dose 
schedule
Booster dose 
schedule
Age-restricted 
scenario*
Age-unrestricted 
scenario
BCG Yes No Yes Yes
DTP1 No No Yes Yes
BCG plus DTP1 Yes No Yes Yes
BCG plus DTP2 Yes No Yes Yes
BCG plus DTP3 Yes No Yes Yes
DTP1 plus DTP2† No No Yes Yes
DTP1 plus DTP3 No No Yes Yes
BCG plus DTP1 plus DTP2‡ Yes No Yes Yes
BCG plus DTP1 plus DTP3 Yes No Yes Yes
BCG plus DTP2 plus DTP3 Yes No Yes Yes
DTP1 plus DTP2 plus DTP3† No No Yes Yes
BCG plus Meas1 Yes Yes No Yes
DTP1 plus Meas1 No Yes No Yes
BCG plus DTP1 plus Meas1 Yes Yes No Yes
BCG plus DTP2 plus Meas1 Yes Yes No Yes
BCG plus DTP3 plus Meas1 Yes Yes No Yes
DTP1 plus DTP2 plus Meas1§ No Yes No Yes
DTP1 plus DTP3 plus Meas1 No Yes No Yes
DTP=diphtheria–tetanus–pertussis. Meas=measles vaccine. *First vaccination before 15 weeks of age; final vaccination 
before 32 weeks of age. †Schedules recommended by WHO; the three-dose schedule has been evaluated in efficacy trials 
for Rotarix, RotaTeq, ROTAVAC, ROTASIIL, and RV3-BB; the two-dose schedule has been evaluated in Rotarix efficacy 
studies.7 ‡Schedule evaluated in RV3-BB efficacy study in Indonesia.13 §Schedule evaluated in Rotarix immunogenicity 
studies in Bangladesh15 and Mali.14
Table 1: List of schedules evaluated for co-administration of rotavirus and other vaccines
See Online for appendix
PY × M × Aw × (1 – Vw)
P × (Cd, w – Cd, w – 1) × [Bw × (RRd, 1 – 7  – 1) + Bw + 1 
× (RRd, 8 – 14 – 1) + Bw + 2 × (RRd, 15 – 21 – 1)]
C3w × E3w + (C2w –  C3w) × E2w + (C1w – C2w) × E1w
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Uncertainty and scenario analysis
Deterministic central estimates (ie, best estimates for 
each input parameter) and probabilistic 95% uncertainty 
intervals (UIs) were calculated for 11 age-restricted 
schedules and 18 age-unrestricted schedules. All input 
parameters and their distributions are shown in the 
appendix (p 16). Central estimates were also calculated 
for six what-if scenarios: RRs of intussusception varying 
with under-5 mortality (figure, appendix p 12); double the 
RR of intussusception for the first dose when given after 
15 weeks of age; vaccine efficacy and waning equivalent 
to low-mortality settings; less rapid waning efficacy 
(based on a power function described in detail else-
where);7 less rapid waning efficacy for all primary doses 
administered as part of a neonatal schedule (appendix 
p 14); and pessimistic access to hospital for intussus-
ception cases (based on the proportion of children with 
2 h access to a public hospital).28
Results for each schedule option reflect the totals 
expected in all 135 LMICs if all countries used the same 
schedule. However, to illustrate the maximum potential 
direct effect of the current live oral vaccines, separate 
totals for the model outcomes were calculated to show 
results if each country used the schedule predicted to 
have the highest reduction in rotavirus gastroenteritis 
deaths.
Statistical analysis
We did a random effects meta-analysis of data from self-
controlled case-series (SCCS) studies to calculate pooled 
RRs of intussusception by dose and period. The inverse 
of the variance was used to weight each study. Very few 
studies reported RRs for the periods 8–14 days and 15–21 
days, so we calculated RRs for the period 8–21 days, and 
applied these RRs to both periods (ie, RRd, 8 – 14 and 
RRd, 15 – 21; table 2, appendix p 5). In one scenario, we 
assumed the RRs would vary with the national under-5 
mortality rate, and this was done by fitting a generalised 
linear random effects model with a log-link function to 
the SCCS data using Markov Chain Monte Carlo with 
Gibbs sampling, and assuming a linear relationship 
between the log mean RR and under-5 mortality rate. 
The inverse of the variance was again used to weight 
each study. We compared the goodness of fit (Deviance 
Information Criterion values) for RRs that did and did 
not vary with under-5 mortality (figure, appendix p 12). 
We also ran a random effects meta-analysis using data 
from case control studies to calculate the relative 
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England (Stowe et al, 2016)3
Mexico (Patel et al, 2011)23
Mexico (Velasquez et al, 2012)24
Singapore (Yung et al, 2015)25
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Figure: RR of intussusception 1–7 days and 8–21 days after one and two doses of rotavirus vaccine in base-case risk scenario and alternative risk scenario 
The four panels on the top row represent the base-case risk scenario (relative risks [RRs] do not vary with under-5 mortality rate). The four panels on the bottom row represent an alternative risk 
scenario and assume RRs vary with the national under-5 mortality rate. Solid black lines indicate the median estimate and shaded grey areas represent 95% CIs. Circles and vertical lines represent the 
RR and 95% CIs reported for each individual self-controlled case-series data point. The size of the circle reflects the inverse of the variance (weight attributed to each study). See appendix (p 12) for 
more details about the fitting methods used. RR=relative risk.
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effectiveness of 1 dose compared with 2 or 3 doses of 
rotavirus vaccination (appendix p 15). Random effects 
were used in all meta-analyses due to heterogeneity 
between the different study populations.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
this report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Mortality reduction benefits and intussusception risks 
were calculated for 31 low-income, 51 lower-middle-
income, and 53 upper-middle-income countries. In all 
135 LMICs (a combined birth cohort of about 60 million 
children), around 194 000 rotavirus gastroenteritis deaths 
(95% UI 159 000–257 000; tables 3, 4) were estimated 
in children younger than 5 years without vaccination. 
The model predicted that 18–41% of these deaths could 
be prevented by rotavirus vaccination, depending on 
the schedule used. Around 14 500 background intus-
susception deaths (8000–27 000; tables 3, 4) were 
estimated in children younger than 5 years. In the base-
case vaccination scenario (ie, with the best assumptions), 
the model predicted that no more than 213 additional 
deaths (about 1·5% increase; table 3) would be caused by 
rotavirus vaccination for any schedule evaluated.
For age-unrestricted schedules co-administered with 
DTP, the predicted reduction in rotavirus gastroenteritis 
deaths was 20% for one-dose schedule, 34% for 
two-dose schedule, and 38% for three-dose schedule 
(table 3). The dose efficiency (number of doses required 
to prevent each death) was circa 2800, 3400, and 4600, 
respectively (table 3). A three-dose schedule could 
prevent about 74 000 (59 000–100 000; table 4) rotavirus 
gastroenteritis deaths (38% reduction) and lead to 
201 (77–550) excess intussusception deaths (1·4% inc-
rease; table 4) com pared with no vaccination, resulting 
in a benefit–risk ratio of 369:1 (160:1–895:1). Infants 
who received their first dose before 15 weeks of age and 
their last dose before 32 weeks of age had a benefit–risk 
ratio of 512:1 (218:1–1338:1) compared with 148:1 
(69:1–317:1) among infants vacci nated after these ages 
(table 4). Compared with an age-restricted schedule, 
a schedule without age restrictions was associated 
with about 12 000 (7000–23 000) fewer rotavirus gastro-
enteritis deaths and 79 (29–236) more intussusception 
deaths (table 4). Among children vaccinated outside 
the recommended age range, the benefit–risk ratio 
exceeded 100:1 in 102 (76%) LMICs, but in 14 countries 
(Algeria, Argentina, Equatorial Guinea, Iraq, Libya, 
Mauritius, Moldova, Saint Lucia, Saint Vincent and 
the Grenadines, Samoa, Syria, Tonga, Vanuatu, and 
Vietnam) the ratio was below 50:1 (appendix p 17). The 
model estimated one excess case of intussusception 
per 46 000 fully vaccinated infants (15 000–124 000). 
The risk was lower for children vaccinated inside the 
age windows (one case per 67 000 [22 000–187 000]) 
than those vaccinated out side (one case per 25 000 
[9000–63 000]; appendix p 17).
Neonatal schedules that involve giving the first 
two doses as early as possible (ie, with BCG and DTP1) 
had the fewest excess intussusception deaths and 
favourable benefit–risk ratios compared with other sche-
dules (table 3). A third dose given with Meas1 (ie, BCG 
plus DTP1 plus Meas1) was predicted to prevent more 
rotavirus gastroenteritis deaths without negatively 
impacting the benefit–risk ratio.
If each country were to use the age-unrestricted 
schedule with the highest predicted reduction in 
rotavirus gastroenteritis deaths, there would be more 
rotavirus gastroenteritis deaths averted (about 81 000 vs 
Rotavirus gastroenteritis deaths* Intussusception deaths* Summary indicators*
n Number averted 
vs no vaccine 
(95% uncertainty 
interval)
Reduction in 
deaths vs no 
vaccine (%)
n Excess 
number vs 
no vaccine
Increase 
vs no 
vaccine 
(%)
Number of fully 
vaccinated 
infants per excess 
intussusception 
case
Rotavirus 
gastroenteritis 
deaths averted 
per excess 
intussusception 
death
No vaccine 194 471 
(158 603–257 080)
·· ·· 14 478 
(8028–27 463)
·· ·· ·· ··
Age-restricted 
scenario
131 986 
(106 800–176 694)
62 485 
(47 895–83 238)
32·1% 
(26·1–37·1)
14 600 
(8112–27 709)
122 
(44–322)
0·8% 
(0·3–1·7)
66 530 
(22 330–187 422)
512
(218–1338)
Age-unrestricted 
scenario
120 323 
(97 540–159 450)
74 148 
(59 362–100 227)
38·1% 
(33·1–42·9)
14 678 
(8165–27 807)
201 
(77–550)
1·4% 
(0·6–2·8)
46 222 
(14 647–123 585)
369
(160–895)
Age-unrestricted 
vs age-restricted 
·· 11 663 
(6522–22 532)
6·0% 
(3·4–10·5)
·· 79 
(29–236)
0·5% 
(0·2–1·2)
25 369 
(8579–63 401)
148
(69–317)
Data estimated for children younger than 5 years. *95% uncertainty intervals represent the 2·5th and 97·5th percentiles of probabilistic simulations; see appendix (p 16) for 
more details.
Table 4: Benefits and risks of removing age restrictions for rotavirus vaccine administration in 135 low-income and middle-income countries for a 
three-dose rotavirus schedule co-administered with diphtheria–tetanus–pertussis vaccine
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74 000), fewer intussusception deaths (148 vs 201), and a 
more favourable benefit–risk ratio (550:1 vs 369:1) 
compared with a standard age-unrestricted schedule 
given with DTP (appendix p 21). 
Schedules incorporating a neonatal dose did not 
have the highest predicted reduction in rotavirus 
gastroenteritis deaths if coverage of BCG was zero 
(eg, Grenada, Lebanon, Suriname); coverage of BCG was 
substantially lower than DTP1 (eg, Ethiopia, Indonesia, 
South Africa); or the overall combination of input 
parameters (rotavirus gastroenteritis age distribution, 
coverage, timeliness, efficacy, and waning) led to 
marginally more rotavirus gastroenteritis deaths 
prevented by infant schedules (eg, Bangladesh). A 
booster dose schedule did not have the highest predicted 
reduction in rotavirus gastroenteritis deaths if age 
restrictions were applied, as very few booster doses are 
administered before 32 weeks of age; most rotavirus 
gastroenteritis deaths were in very young ages 
(eg, Afghanistan, Angola, Pakistan); or the efficacy of 
primary doses was assumed to be high and durable 
(eg, Brazil, Vietnam).
Assuming a gradient of risk consistent with 
under-5 mortality (figure) had a far more favourable 
benefit–risk ratio than the base-case risk assumptions 
(2386:1 vs 369:1 for a three-dose age-unrestricted schedule 
co-administered with DTP). In this scenario, there 
were zero excess intussusception cases in 29 (21%) of 
135 LMICs and fewer than 35 excess intussusception 
deaths each year for any schedule evaluated (appendix 
p 25). If the RR of intussusception for the first dose was 
doubled after 15 weeks of age rather than constant with 
age (appendix p 30), the benefit–risk for children 
vaccinated outside the recommended age range would be 
much lower (66:1 vs 148:1). Assuming vaccine efficacy 
and waning equivalent to low-mortality settings led to 
a much higher reduction in rotavirus gastroenteritis 
deaths (75% vs 42%) if all countries were assumed to 
adopt the schedule with the highest reduction in rotavirus 
gastroenteritis deaths (appendix p 36). A scenario with 
more durable efficacy improved the benefit–risk ratio 
(383:1 vs 369:1 for a three-dose age-unrestricted schedule 
co-administered with DTP) as expected (appendix p 40). 
If doses given as part of a neonatal schedule were 
assumed to have double the mean duration of protection, 
then neonatal schedules had the highest predicted effect 
in most countries (appendix p 46). In a scenario with very 
pessimistic assumptions about access to intussusception 
treatment there were less favourable benefit–risk ratios 
(168:1 vs 369:1 for a three-dose age-unrestricted schedule 
co-administered with DTP) but no more than 480 excess 
intussusception deaths each year for any schedule 
evaluated (appendix p 50).
Discussion
For the current live oral vaccines and schedules 
recommended by WHO, our model estimated 
one excess case of intussusception per approximately 
46 000 fully vaccinated individuals. This risk is more 
favourable than the risk (one excess case per 
<10 000 fully vaccinated individuals) associated with 
RotaShield (Wyeth-Ayerst, Philadelphia, PA, USA), an 
early rota virus vaccine that was withdrawn from the 
market in the USA,31 but less favourable than the risk 
associated with other vaccines, such as BCG vaccine 
(one excess case of disseminated BCG disease per 
>200 000 fully vaccinated individuals)32 and oral polio 
vaccine (one excess case of vaccine associated paralytic 
poliomyelitis per >700 000 fully vaccinated individuals).33 
However, any estimates of the potential risk should also 
be considered in the context of potential benefits, and 
this analysis continues to provide reassurance about 
the positive benefit–risk profile of the currently licensed 
rotavirus vaccines. The central estimate of the benefit–
risk ratio for an age-unrestricted schedule co-
administered with DTP (369:1) is very similar to the 
previous estimate (371:1),4 with the benefits of rotavirus 
vaccine introduction (74 000 rotavirus gastro enteritis 
deaths averted) still greatly exceeding the risk 
(201 intussusception deaths caused).
In the previous analysis removing age restrictions 
from a standard infant schedule of rotavirus co-
administered with DTP was estimated to reduce 
gastroenteritis deaths by about 47 000 per year and 
increase intussusception deaths by about 300 per year.4 
In the new analysis, the equivalent estimates are much 
lower (about 12 000 rotavirus gastro enteritis deaths 
prevented and 79 excess intus susception deaths) but 
the incremental benefit–risk ratio is very similar 
(148:1 vs 154:1). The new analysis, therefore, still supports 
the WHO recom mendation to remove age restrictions in 
countries where the benefit would greatly exceed the 
risk.5 The predicted mortality reduction benefits were 
much lower because prevacci nation estimates of 
rotavirus mortality are now sub stantially lower.6 The 
number of excess intus susception deaths was also 
much lower because the median age of intussusception 
from updated estimates was higher,9 resulting in fewer 
background intussusception cases around the time the 
first rotavirus dose was administered. In both analyses, 
it was assumed that introducing or removing age 
restrictions for rotavirus vaccines would not lead to 
better or worse adherence to schedules, but more 
evidence is needed from post introduction studies to 
confirm this assumption. In a small number of countries 
(eg, Argentina, Vietnam), the benefit–risk ratio of 
introduction or the removal of age restrictions was less 
obviously favourable. In these countries, the input 
assumptions should be carefully reviewed by local 
experts, and a fuller assessment of the broader economic 
benefits of vaccination should be considered. The 
UNIVAC vaccine decision support model used in this 
analysis has been designed for use at country level, and 
is available to download by Ministries of Health and 
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other national stakeholders who wish to better 
understand the national estimates and explore 
scenarios.17
Only RR estimates based on the SCCS method were 
considered because they are based on large numbers of 
postlicensure vaccine recipients. It is important to note 
that only two SCCS studies, both evaluating Rotarix 
(GlaxoSmithKline Biologicals, London, UK) in Africa,11,12 
have evaluated the postlicensure risk of intussusception 
in high-mortality settings, and in both studies the RR 
was low and the association was not statistically 
significant for any dose or period. In a scenario based 
on a gradient of risk consistent with national 
under-5 mortality, the model predicted far more 
favourable benefit–risk ratios than the base-case 
analysis. However, more evidence is needed from other 
parts of the world before a risk can be completely 
excluded in high-mortality countries. Another important 
consideration is whether rotavirus vaccination might 
simply be triggering intussusception events that would 
otherwise occur in the same children at a later date.34
The RRs used in the model did not vary with age. 
However, since the RR is applied to the background age-
specific incidence of intussusception, the absolute risk 
is still highly age-dependent. Should the RR increase 
at older ages of vaccination,35 then removing age 
restrictions would be less favourable in most countries, 
unless the first dose is co-administered with BCG 
rather than DTP1. Assuming a risk relative to (rather 
than independent of) the background incidence of 
intussusception will always favour neonatal schedules, 
but this advantage is yet to be shown in a large number 
of postlicensure vaccine recipients. However, no excess 
risk was associated with RotaShield doses administered 
before 8 weeks and this effect is consistent with no 
excess risk associated with earlier administration of 
Rotarix (GlaxoSmithKline Biologicals, London, UK) in 
Africa (median age 6 weeks).11
For all 135 LMICs combined, the model estimated 
approximately 14 500 intussusception deaths for children 
younger than 5 years of age, but this number was very 
sensitive to the choice of proxy for access to treatment. 
DTP1 coverage was used because it provides a crude 
indicator of access to basic health services and is 
consistently reported for all LMICs. An alternative proxy 
based on the proportion of children with timely (2 h) 
access to public hospitals gave less favourable benefit–
risk ratios. However, this scenario was probably too 
pessimistic because many intussusception cases in 
Africa are known to present to hospital more than 2 days 
after the onset of symptoms.36 In medium-mortality 
countries, access to care adjustments led to large 
increases in the background intussusception mortality 
relative to the (often very low) prevaccination rotavirus 
gastroenteritis mortality. This increase partly explains 
the modest benefit–risk ratio in some countries. For 
example, in Argentina, the model assumed that 5% of 
intussusception cases would not reach hospital (based on 
a proxy of 95% DTP1 coverage)37 and that 90% of these 
children would die. In these settings, an assumption of 
100% access to treatment (consistent with countries in 
the low-mortality and very low-mortality strata) might be 
more appropriate. Improved estimates of treatment use 
for intussusception are needed.
Children at greater risk of rotavirus gastroenteritis 
mortality might be less likely to have access to routine 
vaccination programmes, and not accounting for this 
issue could have led to inflated numbers of rotavirus 
gastroenteritis deaths prevented.38 However, children with 
better access to vacci nation might also have better access 
to intus susception treatment (and hence lower case 
fatality ratios for intussusception than the cohort as a 
whole), and not accounting for this scenario could also 
lead to inflated estimates of intussusception deaths in 
vaccinated children. Thus, adjustments for heterogeneities 
in risk and access are likely to balance out, to some extent 
at least.
This analysis highlights the potential value of a 
neonatal dose of rotavirus vaccination, in terms of both 
safety and impact. The safety of a neonatal dose is yet to 
be shown in a large-scale postlicensure setting, but this 
analysis predicts that fewer intussusception events 
would be caused by the vaccine if neonatal schedules 
were used. The only vaccine to have shown clinical 
efficacy using a neonatal schedule is the RV3-BB 
(Murdoch Children’s Research Institute, Melbourne, 
VA, Australia),13 and it is unclear whether Rotarix 
(GlaxoSmithKline Biologicals, London, UK), RotaSIIL 
(Serum Institute of India, Pune, India), RotaTeq (Merck, 
Kenilworth, NJ, USA), and ROTAVAC (Bharat Biotech, 
Hyderabad, India) would have similar results. It should 
be noted that when RotaShield was studied using a 
neonatal schedule, it was found to be safe and 
efficacious.39 In some countries, neonatal schedules did 
not have the highest predicted effect because coverage of 
BCG was substantially lower than DTP1. However, in 
these countries, the calculations of vaccine effect did not 
allow for opportunities to catch up on missed doses at 
later visits. Also, in some settings BCG might not be the 
best proxy for the coverage and timeliness of the neonatal 
dose of rotavirus vaccination. For example, in Indonesia, 
a neonatal schedule did not have the highest predicted 
effect because the target age for BCG is later than in 
other settings (can be given at any time in the first 
2 months of life), and coverage of BCG is much lower 
than DTP1 (80% vs 95%).37 Thus, the neonatal dose of 
oral polio vaccine or hepatitis B vaccine would have been 
a better choice of proxy in this setting.
This analysis also highlights the potential benefit of 
a booster dose in mitigating the waning protection 
of rotavirus vaccines.40 A third dose of rotavirus vacci-
nation co-administered with Meas1 was assumed to have 
the same efficacy (and waning) as a second dose co-
administered with DTP. This assumption is con sistent 
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with a Rotarix immunogenicity study in Bangladesh, 
where seropositivity (immunoglobulin A titres 
≥20 units per mL) increased from 53% to 70% when 
a third dose of Rotarix was administered concurrently 
with measles vaccine.15 A study in Mali also found an 
increase in immunoglobulin A titres and no negative 
effect on the immune response of other vaccines 
administered at the same visit (eg, measles, yellow 
fever).14 However, more evidence is needed on the safety, 
efficacy, and incremental cost-effectiveness of a booster 
dose, and until this evidence emerges, the results of this 
analysis should be interpreted with caution. Most of the 
excess cases associated with RotaShield were vaccinated 
as part of a catch-up campaign among older infants,41 
although these cases were associated with the first 
and second dose, and no excess risk has been reported 
with the third dose of RotaTeq administered at about 
6 months.15
If all 135 LMICs were to adopt the age-unrestricted 
schedule with the highest predicted reduction in rota-
virus gastroenteritis deaths (including schedules with 
neonatal doses, booster doses, or both), 81 000 associated 
deaths could be averted (42% reduction) compared with 
74 000 (38% reduction) for schedules co-administered 
with DTP. The risk would also be lower because these 
schedules typically involve administering the first dose 
with BCG when the background risk of intussusception 
is lower. However, if a rotavirus vaccine could be 
developed for LMICs with the same efficacy and duration 
of protection observed in high-income countries, a far 
greater number of deaths (about 146 000) could be averted 
(75% reduction). However, the predicted reduction in 
rotavirus gastro enteritis deaths is just one of many 
possible decision criteria that should be considered when 
selecting a schedule. Other criteria include the expected 
risks, benefit–risk, operational feasibility, cost, cost-
effective ness, and public acceptance. In this analysis, 
schedules that involve giving the first dose with BCG and 
the second dose with DTP1 had lower risk and favourable 
benefit–risk results, so warrant serious consideration. 
The choice of schedule should be informed by a detailed 
country-led review of inputs and careful consideration of 
the different trade-offs involved.
A transparent static cohort model was used to estimate 
the potential direct effects of vaccination by week of age. 
Inclusion of herd effects could make the benefit–risk 
ratios more favourable in some settings, but it would be 
challenging to obtain robust estimates of the scale and 
duration of these effects in each of the 135 LMICs. 
Transmission dynamic models calibrated to data from 
Niger42 and India43 have predicted a minimal contri-
bution of indirect effects to overall vaccine effect, and 
although short-term herd effects have been observed in 
El Salvador,44 Ghana,1 Moldova,1 and Rwanda,45 no 
substantial herd effects were observed in Malawi,46 
South Africa,47 Tanzania,1 and Zambia.48 In principle, 
transmission dynamic models could be used to 
anticipate the longer-term effect and relative advantages 
of different vaccination schedule options but these 
models will require access to good quality data on 
disease surveillance and social contact patterns in 
narrow age groups.
When RotaShield was removed from the market in 
the USA, ethicists argued that “the future of a potentially 
lifesaving vaccine for developing countries has been 
imperilled by its recent withdrawal”.49 A central argument 
was that inaction was not a morally neutral state, and that 
“if one is culpable for vaccine related deaths, then one is 
also culpable for deaths caused by withholding the 
vaccine”.49 However, it is also important to consider how 
individual families and caregivers perceive potential 
benefits and risks, how they differ from those who are 
responsible for the public health of the population,50 and 
how they vary across countries. In a study of public 
perceptions in the UK, a disease case caused by 
vaccination was weighted three-times as important as a 
disease case prevented by vaccination.51 This finding is 
consistent with high uptake of rotavirus vaccines in 
the UK (and other high-income settings) despite the 
clearly documented small elevated intussusception risk. 
However, perceptions around deaths are likely to be very 
different, and this issue is particularly important to 
understand in LMICs, where the overwhelming majority 
of rotavirus and intussusception deaths occur. Encour-
agingly, the initial safety studies from high-mortality 
settings have indicated no elevated risk of intussusception 
and coverage and uptake of rotavirus vaccines has been 
high. Good quality postlicensure surveillance will be 
essential to monitor the benefits and risks of rotavirus 
vaccination over time.
This analysis lends further support to the favourable 
benefit–risk profile of rotavirus vaccines in LMICs. 
Neonatal schedules have the potential to increase benefits 
further while reducing risks, but more efficacious 
rotavirus vaccines would be needed to achieve more 
substantial improvements in impact.
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